MedTrace Logo

Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations

NCT00792363 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2012-06-13

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect and the side effect profile of irinotecan and panitumumab administered every 3 weeks as 3rd line treatment for patients with metastatic colorectal cancer without KRAS mutations.

Conditions

Interventions

DRUG

Irinotecan

350 mg/m2 intravenously on day 1 every 3 weeks

DRUG

Panitumumab

9 mg/kg intravenously on day 1 every 3 weeks

Sponsors & Collaborators

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Anders Jakobsen, Professor · Vejle Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-12-31
Completion
2011-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00792363 on ClinicalTrials.gov